A review of public information. No hands-on testing, laboratory inspection or medical review is claimed.
What can be read without starting intake
The current public site offers semaglutide and tirzepatide options and describes an online clinical process. We did not complete an eligibility quiz, provide health details or obtain a patient-specific quotation. This review therefore covers the public menu and terms rather than a completed consultation or pharmacy order.
Sources: RemedyMeds — treatment selection, RemedyMeds — terms of service, FDA — concerns with unapproved GLP-1 drugs
Why older advertised prices are absent
Previously indexed dollar figures do not establish today’s selected formulation, plan or supply period. The current public page reviewed for this edition did not expose a usable dollar quote. Both product records say Quote required; neither an unknown medication cost nor a missing membership fee is treated as free.
Sources: RemedyMeds — treatment selection, RemedyMeds — terms of service, FDA — concerns with unapproved GLP-1 drugs
Read the guarantee with the agreement
The website advertises a conditional outcome-related guarantee. Eligibility, required participation, documentation and the governing service agreement matter more than the headline. Do not assume that stopping early, changing a prescription or being dissatisfied creates an unconditional refund. Ask which charges are refundable and retain the terms supplied at enrollment.
Sources: RemedyMeds — treatment selection, RemedyMeds — terms of service, FDA — concerns with unapproved GLP-1 drugs
Our assessment
The main unresolved comparison is financial: a prospective patient needs the actual total due now, subsequent billing, medication identity and included clinical services. A public offer for a GLP-1 ingredient does not establish that an FDA-approved brand is supplied. This is an information review, with no independent verification of outcomes or guarantee approvals.
Sources: RemedyMeds — treatment selection, RemedyMeds — terms of service, FDA — concerns with unapproved GLP-1 drugs
Every offer in our file.
Semaglutide treatment option
Formulation to confirmThe public site names this treatment option, but no current dollar quote was exposed in the reviewed page.
Tirzepatide treatment option
Formulation to confirmThe public site names this treatment option, but no current dollar quote was exposed in the reviewed page.
Follow the evidence
Sources & price notes
Each source retains its own check date. Provider pages document advertised terms; they do not independently establish clinical outcomes.
- RemedyMeds — treatment selection ↗
The public page offers semaglutide and tirzepatide options but did not expose a current dollar quote. Historical $299/$399 figures were not reused.
Checked October 9, 2026
- RemedyMeds — terms of service ↗
Terms apply to subscriptions, clinical services and any conditional guarantee. Marketing language does not establish an unconditional refund.
Checked October 9, 2026
- FDA — concerns with unapproved GLP-1 drugs ↗
Safety, dosing errors, salt forms and misleading online marketing. Regulatory page rechecked October 9, 2026; retain distinctions between approval, risk information and compounding nominations.
Checked October 9, 2026